Elevance Health, Inc. (ELV)
(Real Time Quote from BATS)
$498.09 USD
-7.07 (-1.40%)
Updated Oct 3, 2024 03:55 PM ET
After-Market: $498.28 +0.19 (0.04%) 4:16 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$498.09 USD
-7.07 (-1.40%)
Updated Oct 3, 2024 03:55 PM ET
After-Market: $498.28 +0.19 (0.04%) 4:16 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
Zacks News
NuVasive (NUVA) Q2 Earnings Meet Estimates, Margins Down
by Zacks Equity Research
NuVasive's (NUVA) second-quarter 2023 results reflect the robust performance of the U.S. Cervical business.
CVS Health (CVS) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Pharmacy drug mix, growth in specialty pharmacy, brand inflation and the acquisitions of Oak Street Health and Signify Health drive CVS Health's (CVS) Q2 revenues.
Penumbra (PEN) Q2 Earnings Top Estimates, Sales View Raised
by Zacks Equity Research
Penumbra's (PEN) U.S. thrombectomy records 50% year-over-year growth, while the international Vascular business sees relatively flat sales in the second quarter.
Exact Sciences (EXAS) Beats on Q2 Earnings, Ups '23 Sales View
by Zacks Equity Research
Strength in Screening revenues and Precision Oncology drive Exact Sciences (EXAS) Q2 performance.
AmerisourceBergen (ABC) Beats on Q3 Earnings, Ups '23 EPS View
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.
Revvity (RVTY) Beats on Q2 Earnings, Lowers '23 EPS View
by Zacks Equity Research
Revvity's (RVTY) second-quarter results reflect the impact of lower COVID-related sales. Both earnings and sales outpace their respective consensus estimate.
Omnicell (OMCL) Q2 Earnings and Revenues Top, '23 View Raised
by Zacks Equity Research
Omnicell's (OMCL) second-quarter 2023 performance reflects strength in advanced services and technical services as well as continued strong execution.
Tenet Healthcare (THC) Q2 Earnings Beat on Solid Hospital Unit
by Zacks Equity Research
Tenet Healthcare's (THC) Q2 results gain on improved adjusted admissions and higher pricing yield. Management expects adjusted EPS of $5.18-$6.03 for this year.
Hologic's (HOLX) Q3 Earnings Beat Estimates, 2023 View Up
by Zacks Equity Research
Strength in Breast Health and GYN Surgical drives Hologic's (HOLX) Q3 performance.
IDEXX (IDXX) Q2 Earnings and Revenues Beat Estimates, View Up
by Zacks Equity Research
IDEXX (IDXX) delivers better-than-expected earnings and revenues in the second quarter of 2023, backed by CAG Diagnostics' recurring revenue growth.
Zimmer Biomet (ZBH) Q2 Earnings Match Estimates, View Raised
by Zacks Equity Research
Barring S.E.T., Zimmer Biomet (ZBH) records strong growth across each of its business segments in the second quarter.
Avantor (AVTR) Q2 Earnings Lag Estimates, FY23 View Revised
by Zacks Equity Research
Despite Avantor's (AVTR) strength in end markets, it reports an overall soft second-quarter performance.
Ensign Group (ENSG) Beats on Q2 Earnings, Raises '23 EPS View
by Zacks Equity Research
Ensign Group's (ENSG) second-quarter results benefit from improved occupancies, skilled and managed care revenue. Rising expenses acted as a partial offset.
Integer Holdings (ITGR) Q2 Earnings Top Estimates, FY23 View Up
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.
Centene (CNC) Q2 Earnings Beat Estimates on Membership Growth
by Zacks Equity Research
Centene's (CNC) Q2 results benefit from growing premium and service revenues coupled with improving membership.
Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Dip
by Zacks Equity Research
Strength in Hugh Acuity Care segment and Hospice division drive Amedisys (AMED) Q2 performance.
Integra's (IART) Q2 Earnings Top Estimates, 2023 View Cut
by Zacks Equity Research
In CSS, Integra (IART) registers strong growth owing to high single-digit growth in Advanced Energy and mid-single-digit growth in CSF management during Q2.
DexCom (DXCM) Q2 Earnings Beat Estimates, Volumes Remain Strong
by Zacks Equity Research
DexCom's (DXCM) second-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Neogen (NEOG) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Neogen (NEOG) Q4 fiscal 2023 results reflect core growth in both operating segments despite softening market conditions.
LabCorp (LH) Q2 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
A rise in organic revenues, acquisitions, net of divestitures and foreign currency translation drive LabCorp's (LH) Q2 revenues.
HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2023 EPS View
by Zacks Equity Research
HCA Healthcare's (HCA) Q2 results benefit from improving patient volumes and surgeries. However, rising expenses acted as a partial offset.
Edwards Lifesciences (EW) Q2 Earnings Top Estimates, View Up
by Zacks Equity Research
The growing adoption of the PASCAL Precision system in Europe and the United States and Edwards' premium products across all regions have driven Edwards Lifesciences' (EW) Q2 revenues.
Boston Scientific (BSX) Q2 Earnings Beat, Margins Improve
by Zacks Equity Research
Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the second quarter.
CONMED (CNMD) Beats on Q2 Earnings, Ups '23 EPS View
by Zacks Equity Research
CONMED's (CNMD) adjusted second-quarter earnings and sales recover from the disruption in the last two quarters due to implementation of a new warehouse management system.
Baxter (BAX) Beats on Q2 Earnings, Revises 2023 EPS Guidance
by Zacks Equity Research
Baxter's (BAX) second-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.